Our MedIcInes

ViiV Healthcare remains committed to developing and investing in new medicines and innovations that aim to improve the treatment success and quality of life of all people living with HIV.

We hope you find the ViiV Exchange a valuable resource to learn more about our current medicines, clinical data and prescribing information.

Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

TRIUMEQ (dolutegravir/ abacavir/ lamivudine) is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.
Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Tivicay (dolutegravir) 10/25/50 mg film-coated tablets are indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age or older and weighing at least 14kg.

Tivicay (dolutegravir) 5 mg dispersible tablets are indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

DOVATO (Dolutegravir/lamivudine)

Dolutegravir (DTG)

Dolutegravir (DTG) has been studied across diverse patient populations as part of both 3-drug and 2-drug regimens, including patients who are virologically suppressed, treatment-experienced or treatment-naïve.

Read more

PM-GB-HVU-WCNT-200001  | April 2021